SG11202103694UA - Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof - Google Patents

Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof

Info

Publication number
SG11202103694UA
SG11202103694UA SG11202103694UA SG11202103694UA SG11202103694UA SG 11202103694U A SG11202103694U A SG 11202103694UA SG 11202103694U A SG11202103694U A SG 11202103694UA SG 11202103694U A SG11202103694U A SG 11202103694UA SG 11202103694U A SG11202103694U A SG 11202103694UA
Authority
SG
Singapore
Prior art keywords
tricyclic
inhibitors
compositions
methods
janus kinase
Prior art date
Application number
SG11202103694UA
Inventor
Zhaokui Wan
Michael Lawrence Vazquez
Original Assignee
Lynk Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lynk Pharmaceuticals Co Ltd filed Critical Lynk Pharmaceuticals Co Ltd
Publication of SG11202103694UA publication Critical patent/SG11202103694UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202103694UA 2018-11-01 2019-11-01 Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof SG11202103694UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862754029P 2018-11-01 2018-11-01
PCT/CN2019/115069 WO2020088659A1 (en) 2018-11-01 2019-11-01 Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof

Publications (1)

Publication Number Publication Date
SG11202103694UA true SG11202103694UA (en) 2021-05-28

Family

ID=70464625

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103694UA SG11202103694UA (en) 2018-11-01 2019-11-01 Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof

Country Status (13)

Country Link
US (3) US12024516B2 (en)
EP (1) EP3856742B1 (en)
JP (1) JP2022506908A (en)
KR (1) KR20210090173A (en)
CN (2) CN118406052A (en)
AU (2) AU2019372677B2 (en)
BR (1) BR112021008128A2 (en)
CA (1) CA3115897A1 (en)
IL (1) IL282786A (en)
MX (1) MX2021004517A (en)
SG (1) SG11202103694UA (en)
TW (1) TWI842766B (en)
WO (1) WO2020088659A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113637018A (en) * 2020-04-27 2021-11-12 苏州晶云药物科技股份有限公司 Crystal form of sulfonamide compound and preparation method thereof
AU2021339071A1 (en) * 2020-09-08 2023-05-25 Galderma Holding SA Novel jak inhibitor compounds, method for synthesizing same and use thereof
CN114149428B (en) * 2020-09-08 2023-06-13 中国药科大学 Pyrido ring compound, and preparation method, intermediate, composition and application thereof
EP4210827A1 (en) * 2020-09-14 2023-07-19 Galderma Holding SA Novel jak inhibitor compounds, method for synthesizing same and use thereof
JP2024531822A (en) * 2021-12-21 2024-08-29 イーヨウ バイオテック (シャンハイ) カンパニー リミテッド Pyridine fused ring compounds and their preparation, intermediates, compositions and uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (en) 1985-10-03 1988-12-02 Merck Sharp & Dohme LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION
ATE141502T1 (en) 1991-01-15 1996-09-15 Alcon Lab Inc USE OF CARRAGEENAN IN TOPICAL OPHTHALMOLOGICAL COMPOSITIONS
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO2007005643A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxyphenylpropanamines
US20070116643A1 (en) 2005-07-01 2007-05-24 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
JP5301991B2 (en) 2005-07-29 2013-09-25 コンサート ファーマシューティカルズ インコーポレイテッド Novel benzo [d] [1,3] -dioxole derivatives
CA2616366A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
TW201612182A (en) 2008-06-10 2016-04-01 Abbvie Inc Novel tricyclic compounds
DE102009033309B4 (en) * 2009-07-15 2019-08-14 Continental Automotive Gmbh Portable remote control device
ES2637588T3 (en) * 2009-12-01 2017-10-13 Abbvie Inc. New tricyclic compounds
CA2781578A1 (en) * 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
EP2924026A1 (en) * 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors

Also Published As

Publication number Publication date
WO2020088659A1 (en) 2020-05-07
EP3856742B1 (en) 2024-10-02
EP3856742A4 (en) 2022-06-22
US12024516B2 (en) 2024-07-02
AU2019372677B2 (en) 2024-05-30
JP2022506908A (en) 2022-01-17
AU2024205760A1 (en) 2024-08-29
TWI842766B (en) 2024-05-21
BR112021008128A2 (en) 2021-08-03
CN113396150B (en) 2024-03-12
EP3856742A1 (en) 2021-08-04
US11851431B2 (en) 2023-12-26
US20220009927A1 (en) 2022-01-13
IL282786A (en) 2021-06-30
CN113396150A (en) 2021-09-14
KR20210090173A (en) 2021-07-19
US20230339950A1 (en) 2023-10-26
TW202035408A (en) 2020-10-01
US20230357247A1 (en) 2023-11-09
MX2021004517A (en) 2021-11-04
US11858933B2 (en) 2024-01-02
AU2019372677A1 (en) 2021-05-13
CA3115897A1 (en) 2020-05-07
CN118406052A (en) 2024-07-30

Similar Documents

Publication Publication Date Title
IL282468A (en) 2- amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
IL282786A (en) Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
SA520411990B1 (en) Compounds useful for inhibiting cyclin-dependent kinase 7
IL276082B1 (en) Dna-pk inhibitor compounds, compositions comprising same and uses thereof
SG11202011513RA (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
EP4331585A3 (en) Inhibitors of ret
EP3806858A4 (en) Kinase inhibitor salts and compositions thereof
EP3672973A4 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
EP3368538A4 (en) Wee 1 kinase inhibitors and methods of making and using the same
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
HK1258764A1 (en) Janus kinases inhibitors, compositions thereof and use thereof
EP3877371A4 (en) Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
SG11202108552QA (en) Compounds, compositions and methods
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
IL276080A (en) Dna-pk inhibitor compounds, compositions comprising same and uses thereof
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
IL278758A (en) Vmat2 inhibitor compounds, compositions, and methods relating thereto
IL280809B (en) Novel compositions, their use, and methods for their formation
ZA201906887B (en) Bruton's tyrosine kinase inhibitors
EP3876939A4 (en) Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
IL283599A (en) Tyrosine kinase inhibitors, compositions and methods there of
EP3876930A4 (en) Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
ZA201904190B (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
ZA202102261B (en) Spak kinase inhibitors as neuroprotective agents
EP4041236A4 (en) Tricyclic kinase inhibitors and uses thereof